Alpha-1 acid glycoprotein (AGP), a glycoprotein constituting 55–140 mg/dL of plasma, features five N-linked glycan chains comprising 40–45% of its mass, including sialylated bi-/tri-/tetra-antennary structures critical for ligand interactions. Thus contributing to its use as a standard for glycosylation studies. As a major acute-phase reactant, AGP surges up to 5-fold during inflammation, synergizing with haptoglobin to diagnose acute inflammation and differentiate hepatic vs. obstructive jaundice. Its glycosylation profile shifts in pathologies: acute inflammation increases bi-antennary and α1,3-fucosylated glycans, while chronic states enhance tri-/tetra-antennary fucosylation. AGP binds progesterone 15× more avidly than albumin and complexes with vitamin B-12 when sialic acid-deficient, influencing drug pharmacokinetics and nutrient transport.

AGP modulates immunity via TLR-2/4 interactions, exacerbating TLR-2-mediated sepsis mortality while inhibiting LPS-driven NETosis. Dysregulated AGP correlates with rheumatoid arthritis, Waldenström macroglobulinemia, and metastatic cancers, where glycoforms alter platelet aggregation and neutrophil adhesion. The AGP:haptoglobin ratio aids in diagnosing bone marrow disorders and hemolytic anemia, reflecting erythropoietic activity Therapeutically, AGP’s drug-binding capacity informs personalized dosing for basic drugs (e.g., chlorpromazine), while engineered glycoforms are explored for targeted anti-inflammatory therapies.